secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0001493152-23-007916
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Q4 2022: product revenue +220% YoY, net income positive; CEO sees 2023 doubling
--------------------------------------------------------------------------------

- Q4 net revenue $8.5M (incl. $5M milestone); product/royalty $3.5M (+220% YoY, +9% QoQ).
- Net income $0.9M ($0.04 diluted EPS); gross profit $6.4M; cash $16.3M at Dec 31, 2022.
- Eighth straight sequential product revenue growth; CEO expects at least 2x product/royalty revenue in 2023.
- Expanded rare disease sales force to 12 specialists; Betaine launch imminent; Dehydrated Alcohol NDA action date June 27, 2023.
- Acquired ET-600 (rare pediatric endocrinology); ET-400 NDA expected by end of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000149315223007916/0001493152-23-007916-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000149315223007916/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-007916

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer